IMMUNOVANT INC (IMVT) — insider trading
Health Care · NASDAQ
IMMUNOVANT INC (IMVT) has 63 reported SEC Form 4 insider transactions in our data, including 35 open-market sales among the most recent 63 (latest 2026-10-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Venker Eric | Director, Officer (Chief Executive Officer) | Open-market sale | 3,506 | $34.11 | $119.6K | Form 4 |
| 2026-10-01 | Venker Eric | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 92,187 | — | $0 | Form 4 |
| 2026-10-01 | Venker Eric | Director, Officer (Chief Executive Officer) | Disposition to the issuer | 85,886 | $33.65 | $2.89M | Form 4 |
| 2026-10-01 | Venker Eric | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 92,187 | $14.46 | $1.33M | Form 4 |
| 2026-09-23 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 2,846 | $36.36 | $103.5K | Form 4 |
| 2026-08-28 | Pande Atul | Director | Option exercise / conversion (derivative) | 1,500 | — | $0 | Form 4 |
| 2026-08-28 | Pande Atul | Director | Open-market sale | 1,500 | $43.27 | $64.9K | Form 4 |
| 2026-08-28 | Pande Atul | Director | Option exercise / conversion | 1,500 | $8.43 | $12.6K | Form 4 |
| 2026-08-20 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 3,056 | $44.16 | $135.0K | Form 4 |
| 2026-07-24 | Pande Atul | Director | Option exercise / conversion (derivative) | 1,500 | — | $0 | Form 4 |
| 2026-07-24 | Pande Atul | Director | Open-market sale | 1,500 | $39.80 | $59.7K | Form 4 |
| 2026-07-24 | Pande Atul | Director | Option exercise / conversion | 1,500 | $8.43 | $12.6K | Form 4 |
| 2026-07-23 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 2,857 | $38.69 | $110.5K | Form 4 |
| 2026-07-23 | Girao Tiago | Officer (Chief Financial Officer) | Open-market sale | 6,798 | $38.69 | $263.0K | Form 4 |
| 2026-07-08 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 77 | $39.99 | $3.1K | Form 4 |
| 2026-07-08 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 1,399 | $39.53 | $55.3K | Form 4 |
| 2026-07-08 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 105 | $39.99 | $4.2K | Form 4 |
| 2026-07-08 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 1,906 | $39.53 | $75.3K | Form 4 |
| 2026-07-08 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 63 | $39.99 | $2.5K | Form 4 |
| 2026-07-08 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 1,143 | $39.53 | $45.2K | Form 4 |
| 2026-07-08 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 106 | $39.99 | $4.2K | Form 4 |
| 2026-07-08 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 1,930 | $39.53 | $76.3K | Form 4 |
| 2026-07-02 | Venker Eric | Director, Officer (Chief Executive Officer) | Open-market sale | 3,092 | $38.48 | $119.0K | Form 4 |
| 2026-07-01 | Venker Eric | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 92,188 | — | $0 | Form 4 |
| 2026-07-01 | Venker Eric | Director, Officer (Chief Executive Officer) | Disposition to the issuer | 86,629 | $38.14 | $3.30M | Form 4 |
| 2026-07-01 | Venker Eric | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 92,188 | $14.46 | $1.33M | Form 4 |
| 2026-06-26 | Pande Atul | Director | Option exercise / conversion (derivative) | 1,500 | — | $0 | Form 4 |
| 2026-06-26 | Pande Atul | Director | Open-market sale | 1,500 | $38.01 | $57.0K | Form 4 |
| 2026-06-26 | Pande Atul | Director | Option exercise / conversion | 1,500 | $8.43 | $12.6K | Form 4 |
| 2026-06-26 | Girao Tiago | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-26 | Girao Tiago | Officer (Chief Financial Officer) | Open-market sale | 10,000 | $38.46 | $384.6K | Form 4 |
| 2026-06-26 | Girao Tiago | Officer (Chief Financial Officer) | Option exercise / conversion | 10,000 | $15.90 | $159.0K | Form 4 |
| 2026-06-26 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 17,824 | — | $0 | Form 4 |
| 2026-06-26 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 2,842 | $38.96 | $110.7K | Form 4 |
| 2026-06-26 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 14,982 | $38.19 | $572.2K | Form 4 |
| 2026-06-26 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Option exercise / conversion | 17,824 | $15.20 | $270.9K | Form 4 |
| 2026-06-26 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 6,723 | $38.94 | $261.8K | Form 4 |
| 2026-06-26 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 33,277 | $38.18 | $1.27M | Form 4 |
| 2026-06-26 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 2,966 | $38.95 | $115.5K | Form 4 |
| 2026-06-26 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 14,748 | $38.18 | $563.1K | Form 4 |
| 2026-06-18 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 2,634 | $35.39 | $93.2K | Form 4 |
| 2026-06-15 | Pande Atul | Director | Option exercise / conversion (derivative) | 1,500 | — | $0 | Form 4 |
| 2026-06-15 | Pande Atul | Director | Open-market sale | 1,500 | $34.02 | $51.0K | Form 4 |
| 2026-06-15 | Pande Atul | Director | Option exercise / conversion | 1,500 | $8.43 | $12.6K | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion (derivative) | 16,260 | — | $0 | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion (derivative) | 77,181 | — | $0 | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion (derivative) | 71,492 | — | $0 | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion (derivative) | 31,668 | — | $0 | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Open-market sale | 210,468 | $33.56 | $7.06M | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Open-market sale | 11,483 | $32.64 | $374.8K | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion | 16,260 | $14.70 | $239.0K | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion | 77,181 | $8.43 | $650.6K | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion | 71,492 | $7.94 | $567.6K | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion | 31,668 | $4.99 | $158.0K | Form 4 |
| 2026-05-20 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 1,698 | $32.95 | $55.9K | Form 4 |
| 2026-05-20 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 1,168 | $32.15 | $37.6K | Form 4 |
| 2026-05-20 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 249 | $30.41 | $7.6K | Form 4 |
| 2026-05-20 | Pande Atul | Director | Option exercise / conversion (derivative) | 6,000 | — | $0 | Form 4 |
| 2026-05-20 | Pande Atul | Director | Open-market sale | 6,000 | $32.00 | $192.0K | Form 4 |
| 2026-05-20 | Pande Atul | Director | Option exercise / conversion | 6,000 | $8.43 | $50.6K | Form 4 |
| 2026-05-01 | Susman Robert Graham | Director | Open-market sale | 2,502 | $27.17 | $68.0K | Form 4 |
| 2026-04-23 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 2,754 | $29.62 | $81.6K | Form 4 |
| 2026-04-23 | Girao Tiago | Officer (Chief Financial Officer) | Open-market sale | 25,760 | $29.62 | $763.0K | Form 4 |
Ask the chat about IMVT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: IMMUNOVANT INC (IMVT).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.